Concepts (115)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Infant, Premature, Diseases | 4 | 2025 | 47 | 2.520 |
Why?
|
| Infant, Premature | 7 | 2025 | 183 | 2.080 |
Why?
|
| Infant, Newborn | 15 | 2025 | 1348 | 1.470 |
Why?
|
| Infant, Extremely Premature | 3 | 2025 | 37 | 1.310 |
Why?
|
| Ductus Arteriosus, Patent | 2 | 2020 | 14 | 1.280 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 2 | 2025 | 12 | 1.160 |
Why?
|
| Tidal Volume | 2 | 2025 | 41 | 1.120 |
Why?
|
| Positive-Pressure Respiration | 2 | 2025 | 51 | 1.100 |
Why?
|
| Enterocolitis, Necrotizing | 2 | 2025 | 18 | 1.030 |
Why?
|
| Retinopathy of Prematurity | 2 | 2025 | 13 | 0.990 |
Why?
|
| Delivery Rooms | 2 | 2025 | 4 | 0.970 |
Why?
|
| Infant, Newborn, Diseases | 2 | 2022 | 30 | 0.960 |
Why?
|
| Bronchopulmonary Dysplasia | 3 | 2025 | 31 | 0.810 |
Why?
|
| Intestinal Perforation | 1 | 2022 | 16 | 0.800 |
Why?
|
| Indomethacin | 2 | 2020 | 22 | 0.790 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2024 | 157 | 0.770 |
Why?
|
| Acetaminophen | 2 | 2020 | 58 | 0.750 |
Why?
|
| Hyperoxia | 2 | 2017 | 17 | 0.690 |
Why?
|
| Lung Injury | 2 | 2018 | 34 | 0.690 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2019 | 45 | 0.610 |
Why?
|
| Hemangioma | 1 | 2018 | 28 | 0.580 |
Why?
|
| Lung | 3 | 2018 | 942 | 0.570 |
Why?
|
| Infant | 6 | 2022 | 1638 | 0.560 |
Why?
|
| Cysteine-Rich Protein 61 | 1 | 2017 | 5 | 0.560 |
Why?
|
| Pulmonary Artery | 1 | 2017 | 95 | 0.520 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2017 | 172 | 0.490 |
Why?
|
| Prospective Studies | 4 | 2025 | 3263 | 0.480 |
Why?
|
| Liver Neoplasms | 1 | 2018 | 297 | 0.470 |
Why?
|
| Intubation, Intratracheal | 2 | 2025 | 204 | 0.360 |
Why?
|
| Feasibility Studies | 2 | 2025 | 562 | 0.350 |
Why?
|
| Pregnancy | 6 | 2024 | 2318 | 0.340 |
Why?
|
| Humans | 17 | 2025 | 62942 | 0.310 |
Why?
|
| Female | 11 | 2025 | 32597 | 0.280 |
Why?
|
| Quality of Life | 2 | 2025 | 1216 | 0.280 |
Why?
|
| Male | 9 | 2025 | 29603 | 0.260 |
Why?
|
| Retrospective Studies | 5 | 2024 | 6556 | 0.260 |
Why?
|
| Infant, Low Birth Weight | 3 | 2022 | 60 | 0.250 |
Why?
|
| Child | 3 | 2025 | 4487 | 0.250 |
Why?
|
| Infant, Very Low Birth Weight | 2 | 2024 | 37 | 0.240 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2021 | 76 | 0.220 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2024 | 79 | 0.210 |
Why?
|
| Inflammasomes | 2 | 2017 | 334 | 0.210 |
Why?
|
| Psychotropic Drugs | 1 | 2024 | 81 | 0.210 |
Why?
|
| Adolescent | 2 | 2025 | 6193 | 0.200 |
Why?
|
| Animals, Newborn | 3 | 2018 | 237 | 0.200 |
Why?
|
| Seizures | 1 | 2024 | 144 | 0.200 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2022 | 41 | 0.180 |
Why?
|
| Longitudinal Studies | 1 | 2025 | 1250 | 0.180 |
Why?
|
| Vascular Remodeling | 2 | 2018 | 24 | 0.170 |
Why?
|
| Hypertrophy, Right Ventricular | 2 | 2017 | 7 | 0.170 |
Why?
|
| Delivery, Obstetric | 1 | 2021 | 51 | 0.170 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2021 | 65 | 0.170 |
Why?
|
| Pyrimidines | 2 | 2018 | 135 | 0.170 |
Why?
|
| Hypertension, Pulmonary | 2 | 2018 | 96 | 0.170 |
Why?
|
| Breast Feeding | 1 | 2022 | 149 | 0.160 |
Why?
|
| Follow-Up Studies | 1 | 2025 | 2446 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 1 | 2024 | 729 | 0.160 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2018 | 622 | 0.160 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2018 | 25 | 0.150 |
Why?
|
| Conservative Treatment | 1 | 2018 | 17 | 0.150 |
Why?
|
| Pyrazoles | 1 | 2018 | 78 | 0.140 |
Why?
|
| Thrombocytopenia | 1 | 2018 | 54 | 0.140 |
Why?
|
| Blood Transfusion | 1 | 2018 | 161 | 0.140 |
Why?
|
| Child, Preschool | 1 | 2022 | 1974 | 0.130 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2016 | 17 | 0.130 |
Why?
|
| Neutrophil Infiltration | 1 | 2017 | 60 | 0.130 |
Why?
|
| Neovascularization, Physiologic | 1 | 2017 | 104 | 0.130 |
Why?
|
| Interleukin-1beta | 1 | 2016 | 263 | 0.120 |
Why?
|
| Recombinant Proteins | 1 | 2017 | 701 | 0.120 |
Why?
|
| Pneumonia | 1 | 2017 | 289 | 0.110 |
Why?
|
| Parenteral Nutrition | 1 | 2013 | 21 | 0.100 |
Why?
|
| Growth Disorders | 1 | 2013 | 30 | 0.100 |
Why?
|
| Disease Models, Animal | 2 | 2017 | 2188 | 0.100 |
Why?
|
| Enteral Nutrition | 1 | 2013 | 54 | 0.100 |
Why?
|
| Nutritional Status | 1 | 2013 | 97 | 0.100 |
Why?
|
| Gestational Age | 2 | 2024 | 189 | 0.090 |
Why?
|
| Body Weight | 1 | 2013 | 377 | 0.090 |
Why?
|
| Macrophages | 1 | 2017 | 1039 | 0.090 |
Why?
|
| Socioeconomic Factors | 2 | 2024 | 773 | 0.080 |
Why?
|
| Honey | 1 | 2009 | 1 | 0.080 |
Why?
|
| Toxins, Biological | 1 | 2009 | 6 | 0.080 |
Why?
|
| Time Factors | 1 | 2017 | 3748 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 2156 | 0.080 |
Why?
|
| Pandemics | 2 | 2022 | 668 | 0.070 |
Why?
|
| Animals | 3 | 2018 | 20649 | 0.060 |
Why?
|
| Patient Discharge | 2 | 2022 | 506 | 0.060 |
Why?
|
| Maternal Age | 1 | 2024 | 33 | 0.060 |
Why?
|
| Maternal Health | 1 | 2024 | 15 | 0.060 |
Why?
|
| Pulmonary Surfactants | 1 | 2024 | 12 | 0.060 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2024 | 32 | 0.050 |
Why?
|
| Rats | 2 | 2018 | 1982 | 0.050 |
Why?
|
| Social Class | 1 | 2024 | 133 | 0.050 |
Why?
|
| New England | 1 | 2024 | 273 | 0.050 |
Why?
|
| Aftercare | 1 | 2022 | 75 | 0.050 |
Why?
|
| Multivariate Analysis | 1 | 2024 | 934 | 0.050 |
Why?
|
| Respiration, Artificial | 1 | 2024 | 297 | 0.040 |
Why?
|
| Premature Birth | 1 | 2021 | 111 | 0.040 |
Why?
|
| Pregnancy Outcome | 1 | 2021 | 190 | 0.040 |
Why?
|
| Hospitals | 1 | 2022 | 393 | 0.040 |
Why?
|
| Cell Hypoxia | 1 | 2018 | 42 | 0.040 |
Why?
|
| Pulmonary Alveoli | 1 | 2018 | 41 | 0.040 |
Why?
|
| Cyclic GMP | 1 | 2018 | 30 | 0.040 |
Why?
|
| Bone Development | 1 | 2018 | 31 | 0.040 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2024 | 710 | 0.040 |
Why?
|
| Adult | 3 | 2024 | 16669 | 0.040 |
Why?
|
| Aminoquinolines | 1 | 2016 | 16 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2016 | 233 | 0.030 |
Why?
|
| Massachusetts | 1 | 2021 | 2062 | 0.030 |
Why?
|
| Blood Urea Nitrogen | 1 | 2013 | 9 | 0.030 |
Why?
|
| Nutritional Requirements | 1 | 2013 | 20 | 0.030 |
Why?
|
| Dietary Proteins | 1 | 2013 | 42 | 0.030 |
Why?
|
| Birth Weight | 1 | 2013 | 85 | 0.020 |
Why?
|
| Risk Factors | 1 | 2021 | 5312 | 0.020 |
Why?
|
| Rhododendron | 1 | 2009 | 1 | 0.020 |
Why?
|
| Young Adult | 1 | 2009 | 4646 | 0.010 |
Why?
|